NCT02594215View on ClinicalTrials.gov

Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

June 24, 2022

Conditions
Proteus Syndrome
Interventions
DRUG

MK-7075 (miransertib)

MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Human Genome Research Institute (NHGRI)

NIH

NCT02594215 - Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome | Biotech Hunter | Biotech Hunter